## **CLAIMS**

1. A compound of formula (1):

wherein:

15

20

R¹ represents C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>2-6</sub> alkynyl-Y¹-, aryl-Y¹-, heteroaryl-Y¹-, aryl-(O)<sub>t</sub>-aryl-Y¹-, aryl-(O)<sub>t</sub>-heteroaryl-Y¹-, heteroaryl-(O)<sub>t</sub>-aryl-Y¹-, heteroaryl-O-Y¹-, heteroaryl-O-Y¹-, C<sub>2-6</sub> alkenyl-Y¹-, aryl-O-Y¹-, heteroaryl-O-Y¹-, C<sub>1-6</sub> alkyl-SO<sub>2</sub>-Y¹-, M-Y¹-, J²-Y¹-, -CN or C<sub>3-8</sub> cycloalkyl-Y¹- or C<sub>3-8</sub> cycloalkenyl-Y¹-, which cycloalkyl or cycloalkenyl may be optionally substituted by one or more hydroxyl or C<sub>1-6</sub> alkyl groups;

10 R<sup>2</sup> represents hydrogen or C<sub>1-8</sub> alkyl;

X represents ethylene or a group of formula CReR' wherein Re and R' independently represent hydrogen or C<sub>1-4</sub> alkyl or Re and R' may together with the carbon atom to which they are attached form a C<sub>3-8</sub> cycloalkyl group;

R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl;

Z represents a bond, CO, SO<sub>2</sub>, CR<sup>9</sup>R<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>, (CH<sub>2</sub>)<sub>n</sub>CR<sup>9</sup>R<sup>6</sup>, CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>O, CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>S, CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>OCO, CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>CO, COCHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub> or SO<sub>2</sub>CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>;

 $R^5$  represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, aryl, heteroaryl, aryl- $C_{2-6}$  alkenyl- or a group of formula  $-Y^2-J^1$ :

R<sup>6</sup> represents hydrogen, C<sub>1-4</sub> alkyl, CONR<sup>7</sup>R<sup>8</sup> or COOC<sub>1-6</sub> alkyl;

a and b represent 1 or 2, such that a+b represents 2 or 3;

n represents an integer from 0 to 4;

J<sup>1</sup> and J<sup>2</sup> independently represent a moiety of formula (K):

$$X^1$$
 $X^2$ 
 $(K)$ 

WO 02/26722 PCT/GB01/04345

wherein X¹ represents oxygen, NR¹³ or sulphur, X² represents CH₂, oxygen, NR¹⁰ or sulphur, m¹ represents an integer from 1 to 3 and m² represents an integer from 1 to 3, provided that m¹+m² is in the range from 3 to 5, also provided that when both X¹ and X² represent oxygen, NR¹³, NR¹⁰ or sulphur, m¹ and m² must both not equal less than 2, wherein K is optionally substituted by one or more -Y³-aryl, -Y³-heteroaryl, -Y³-CO-aryl, -COC₃-gcycloalkyl, -Y³-CO-heteroaryl, -C₁-g alkyl, -Y³-COOC₁-g alkyl, -Y³-CO-L-g alkyl, -Y³-CO-W, -Y³-NR¹¹R¹², -Y³-CO-W, -Y³-NR¹¹R¹², -Y³-CONR¹¹R¹², hydroxy, oxo, -Y³-SO₂NR¹¹R¹², -Y³-SO₂C1-g alkyl, -Y³-NR¹4CONR¹¹R¹², -Y³-NR¹4CO

R7, R8, R9, R10, R13, R14 and R15 independently represent hydrogen or C1-6 alkyl;

R<sup>11</sup> and R<sup>12</sup> independently represent hydrogen or C<sub>1-6</sub> alkyl or R<sup>11</sup> and R<sup>12</sup> together with the nitrogen atom to which they are attached may form a morpholine, piperidine or pyrrolidine ring;

M represents a C<sub>3-8</sub> cycloalkyl or a C<sub>3-8</sub> cycloalkenyl group fused to a monocyclic aryl or monocyclic heteroaryl group;

W represents a saturated or unsaturated, non-aromatic 5-7 membered ring containing between 1 and 3 heteroatoms selected from nitrogen, oxygen or sulphur, optionally substituted with one or more  $C_{1-8}$  alkyl, halogen or hydroxy groups;

t represents 0 or 1.

5

10

15

20


25

30

Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> independently represent a bond or a group of formula –(CH<sub>2</sub>)<sub>p</sub>CR<sup>c</sup>R<sup>d</sup>(CH<sub>2</sub>)<sub>q</sub>-wherein R<sup>c</sup> and R<sup>d</sup> independently represent hydrogen or C<sub>1-4</sub> alkyl or R<sup>c</sup> and R<sup>d</sup> may together with the carbon atom to which they are attached form a C<sub>3-8</sub> cycloalkyl group, and p and q independently represent an integer from 0 to 5 wherein p + q is an integer from 0 to 5; and salts and solvates thereof.

2. A compound of formula (I) according to claim 1 wherein  $R^1$ -represents  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $C_{2-6}$  alkynyl,  $C_{2-6}$  alkynyl,  $C_{2-6}$  alkynyl- $Y^1$ -, aryl- $Y^1$ -, heteroaryl- $Y^1$ -,  $Y^1$ -, heteroaryl- $Y^1$ -,  $Y^1$ -,  $Y^1$ -, or  $Y^1$ -, heteroaryl- $Y^1$ -,  $Y^1$ -, or  $Y^1$ -,  $Y^1$ -, or  $Y^1$ 

J¹ represents a moiety of formula (K):



wherein X¹ represents oxygen, NR¹³ or sulphur, X² represents CH₂, oxygen, NR¹⁰ or sulphur, m¹ represents an integer from 1 to 3 and m² represents an integer from 1 to 3, provided that m¹+m² is in the range from 3 to 5, also provided that when both X¹ and X² represent oxygen, NR¹³, NR¹⁰ or sulphur, m¹ and m² must both not equal less than 2, wherein K is optionally substituted by one or more -Y³-aryl, -Y³-heteroaryl, -Y³-CO-aryl, -Y³-CO-heteroaryl, -C₁-β alkyl, -Y³-COC1-β alkyl, -Y³-W, -Y³-CO-W, -Y³-NR¹¹R¹², -Y³-CONR¹¹R¹², hydroxy, oxo, -Y³-SO₂NR¹¹R¹², -Y³-SO₂C1-β alkyl, -Y³-SO₂aryl, -Y³-SO₂heteroaryl, -Y³-NR¹⁴C1-β alkyl, -Y³-NR¹⁴SO₂C1-β alkyl, -Y³-NR¹⁴COOR¹⁵ or -Y³-OCONR¹¹R¹² groups, and is optionally fused to a monocyclic aryl or heteroaryl ring.

3. A compound of formula (I) according to claim 1 wherein  $R^1$  represents  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl,  $C_{2-6}$  alkynyl, aryl- $Y^1$ -, heteroaryl- $Y^1$ -, aryl- $(O)_t$ -aryl- $Y^1$ -, aryl- $(O)_t$ -heteroaryl- $Y^1$ -, heteroaryl- $Y^1$ -,  $Y^1$ -,  $Y^1$ -, heteroaryl- $Y^1$ -,  $Y^1$ -,  $Y^1$ -,  $Y^1$ -, heteroaryl- $Y^1$ -,  $Y^1$ -,

Z represents a bond, CO,  $CR^9R^6(CH_2)_n$ ,  $CHR^6(CH_2)_nO$ ,  $CHR^6(CH_2)_nS$ ,  $CHR^6(CH_2)_nOCO$ ,  $CHR^6(CH_2)_nCO$ ; and

J¹ represents a moiety of formula (K):


5

10

15

20

25



WO 02/26722 PCT/GB01/04345

NR<sup>14</sup>COOR<sup>15</sup> or -Y<sup>3</sup>-OCONR<sup>11</sup>R<sup>12</sup> groups, and is optionally fused to a monocyclic aryl or heteroaryl ring.

- 4. A compound of formula (I) according to any one of claims 1 to 3 wherein R<sup>1</sup> represents aryl-Y<sup>1</sup>-.
- 5 A compound of formula (I) according to claim 4 wherein R¹ represents optionally substituted phenyl-Y¹- in which phenyl may be optionally substituted.
  - 6. A compound of formula (I) according to any one of claims 1 to 5 wherein Y<sup>1</sup> represents -CH<sub>2</sub>-.
  - 7. A compound of formula (I) according to claim 1 wherein X represents methylene.
- 10 8. A compound of formula (I) according to claim 1 wherein a and b both represent 1.
  - 9. A compound of formula (I) according to claim 1 or claim 3 wherein Z represents a bond, CO, CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>, CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>O or CHR<sup>6</sup>(CH<sub>2</sub>)<sub>n</sub>CO.
  - 10. A compound of formula (I) according to claim 9 wherein Z represents CH<sub>2</sub>.

15

25

30

- 11. A compound of formula (I) according to claim 1 wherein R<sup>6</sup> represents phenyl optionally substituted with one or more halogen atoms.
- 12. A compound of formula (I) according to claim 11 wherein R<sup>6</sup> represents 3,4-dichlorophenyl.
- 13. A compound of formula (I) according to any one of claims 1 to 12 as described in Examples 1 to 240 or a salt or solvate of any one thereof.
- 20 14. A compound of formula (I) according to claim 13 which is 2-[3(Aminosulfonyl)phenyl]-N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide or a solvate thereof.
  - 15. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt or solvate thereof in admixture with one or more pharmaceutically acceptable diluents or carriers.
  - 16. A compound of formula (I) as defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt or solvate thereof for use as a pharmaceutical.
  - 17. Use of a compound of formula (I) as defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of inflammatory diseases.
  - 18. A method of treatment or prophylaxis of inflammatory diseases eg. asthma which comprises administering to a patient an effective amount of a compound of formula (I) as defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt or solvate thereof.

- 19. A process for preparing a compound of formula (I) according to any one of claims 1 to 14 which comprises:
- (a) acylation of a compound of formula (II)

$$\begin{array}{c|c}
H & X & O \\
\downarrow & & \downarrow \\
R^2 & (\downarrow)_a & R^4
\end{array}$$

$$\begin{array}{c}
\downarrow & & \\
\downarrow & & \\
Z & & \\
\downarrow & & \\
Z & & \\
R^5
\end{array}$$
(II)

- wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, Z, a and b are as defined in claim 1, with a compound of formula R<sup>1</sup>COOH or an activated derivative thereof, wherein R<sup>1</sup> is as defined in claim 1; or
  - (b) reacting a compound of formula (III)

wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, X, a and b are as defined in claim 1, with a compound of formula

10 L<sup>1</sup>-Z-R<sup>5</sup>, wherein Z and R<sup>5</sup> are as defined in claim 1 and L<sup>1</sup> represents a suitable leaving group; or

- (c) deprotecting a compound of formula (I) which is protected; or
- (d) interconversion of other compounds of formula (i).
- 20. A process for preparing a compound of formula (I) according to any one of claims
  15 1 to 14 which comprises:
  - (e) forming a compound of formula (I) wherein  $R^1$  represents heteroaryI- $Y^1$ -, aryI- $(O)_t$ -heteroaryI- $Y^1$  or heteroaryI- $(O)_t$ -heteroaryI- $Y^1$  (wherein said  $Y^1$  group is attached to heteroaryI via a heterocyclic nitrogen atom) and  $R^2$  represents hydrogen which comprises reacting a compound of formula (IV)

5

10

$$L^{2} \xrightarrow{V^{1}} X \xrightarrow{O} 0 \xrightarrow{()_{b}} R^{3}$$

$$\downarrow Z \qquad \qquad \downarrow Z$$

$$\downarrow Z \qquad \qquad \downarrow Z$$

$$\downarrow Z \qquad \qquad \downarrow Z \qquad \qquad (IV)$$

or a protected derivative thereof wherein R³, R⁴, R⁵, X, Y¹, Z, a and b are as defined in claim 1, L² represents a suitable leaving group, such as a halogen atom eg. bromine and P¹ represents a solid phase resin bound protecting group, with a heterocyclic compound defined by the R¹ groups heteroaryl, aryl-(O)<sub>t</sub>-heteroaryl or heteroaryl-(O)<sub>t</sub>-heteroaryl above wherein said heteroaryl group contains at least one NH atom, followed by removal of the solid phase resin bound protecting group; or

- (f) forming a compound of formula (I) wherein Z represents  $CR^9R^8(CH_2)_n$  and  $R^9$  represents hydrogen which comprises reacting a compound of formula (III) or a protected derivative thereof with a compound of formula  $R^6CO(CH_2)_nR^5$ , followed by reduction of the resultant imine; or
- (g) forming a compound of formula (I) wherein Z represents CO by reacting a compound of formula (III) or a protected derivative thereof with a compound of formula R<sup>5</sup>COOH or an activated derivative thereof.

## 15 21. A compound of formula (II)

wherein R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, Z, a and b are as defined in claim 1 or a protected derivative thereof, or a salt or solvate thereof.

## 22. A compound of formula (III)

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , X, a and b are as defined in claim 1 or a protected derivative thereof, or a salt or solvate thereof.

## 23. A compound of formula (IV)

$$L^{2} \xrightarrow{Y^{1}} X \xrightarrow{O} (1)_{b} R^{3}$$

$$\downarrow Q \qquad \qquad \downarrow R^{4}$$

$$\downarrow Z \qquad \qquad \downarrow R^{5}$$

$$\downarrow Q \qquad \qquad \downarrow R^{5}$$

$$\downarrow Q \qquad \qquad \downarrow R^{5}$$

$$\downarrow Q \qquad \qquad \downarrow R^{5}$$

wherein R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, X, Y<sup>1</sup>, Z, a and b are as defined in claim 1, L<sup>2</sup> represents a suitable leaving group, such as a halogen atom eg. bromine and P<sup>1</sup> represents a solid phase resin bound protecting group, or a salt or solvate thereof.